阿帕替尼联合化疗对一线治疗后进展的晚期非小细胞肺癌患者的临床疗效

Clinical effect of apatinib combined with chemotherapy on patients with advanced non-small cell lung cancer after failure of first-line treatment

目的探讨阿帕替尼联合化疗对一线治疗后进展的晚期非小细胞肺癌(NSCLC)患者的临床疗效。方法根据治疗方法的不同将68例一线治疗后进展的晚期NSCLC患者分为观察组(n=32)和对照组(n=36)。观察组患者接受阿帕替尼联合二线或三线化疗,对照组患者接受单纯二线或三线化疗。比较两组患者的临床疗效、生存情况及不良反应发生情况。结果观察组患者的客观缓解率(ORR)和疾病控制率(DCR)分别为9.38%(3/32)和68.75%(22/32),与对照组的8.33%(3/36)和50.00%(18/36)比较,差异均无统计学意义(P﹥0.05)。观察组患者的无进展生存情况和总生存情况均明显优于对照组,差异均有统计学意义(P﹤0.01)。观察组和对照组患者1~2级高血压、蛋白尿、骨髓抑制、胃肠道反应、手足综合征、皮疹的发生率比较,差异均无统计学意义(P﹥0.05);观察组和对照组患者3~4级上述不良反应的发生率比较,差异均无统计学意义(P﹥0.05)。结论阿帕替尼联合化疗对一线治疗后进展的晚期NSCLC患者疗效较好,可延长患者的生存时间,且具有良好的安全性,值得在临床推广应用。

Objective To analyze the clinical effect of apatinib combined with chemotherapy on patients with advanced non-small cell lung cancer(NSCLC)after failure of first-line treatment.Method 68 patients with advanced NSCLC were stratified by respective treatment administered as study group(n=32)and control group(n=36),respectively.Patients in study group received apatinib combined with second-or third-line chemotherapy,while those in control group were treated with second-or third-line chemotherapy alone.The clinical curative effect,survival and adverse reactions were compared between the two groups.Result The objective response rate(ORR)and disease control rate(DCR)in study group were 9.38%(3/32)and 68.75%(22/32),which were similar to those in control group at 8.33%(3/36)and 50.00%(18/36),respectively,the difference was of no statistical significance(P>0.05).The progression-free survival(PFS)and overall survival(OS)of patients in study group were better compared to those in control group,with statistically significant differences noted(P<0.01).In regard to incidence of adverse reactions of grade 1-2 including hypertension,proteinuria,bone marrow suppression,gastrointestinal reactions,hand-foot syndrome,and rash,no obvious differences were observed between the two groups(P>0.05);similarly,the incidence of above adverse reactions of grade 3-4 were also of no significant difference between study group and control group(P>0.05).Conclusion The regimen of apatinib combined with chemotherapy for patients with NSCLC after failure of first-line treatment is effective,with prolonged survival and acceptable safety.